Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 15/20 | 0.45 |
| ▸ | PDGFRB | P09619 | 9/20 | 0.45 |
| ▸ | PDGFRA | P16234 | 9/20 | 0.45 |
| ▸ | FLT3 | P36888 | 5/20 | 0.45 |
| ▸ | MET | P08581 | 5/20 | 0.44 |
| ▸ | KDR | P35968 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | KIT | P10721 | 1/20 | 0.41 |
| ▸ | WNT1 | P04628 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5064658 | 0.88 | CSF1R (0.41) | CSF1RPDGFRBPDGFRAFLT3MET | |
| SCHEMBL5064719 | 0.87 | CSF1R (0.44) | CSF1RPDGFRBPDGFRAFLT3MET | |
| SCHEMBL574003 | 0.82 | CSF1R (0.55) | CSF1RPDGFRBPDGFRAFLT3MET | |
| SCHEMBL828020 | 0.82 | CSF1R (0.55) | CSF1RPDGFRBPDGFRAFLT3MET | |
| SCHEMBL574217 | 0.81 | AXL (0.55) | CSF1RPDGFRBPDGFRAFLT3MET | |
| SCHEMBL27846589 | 0.81 | KDR (0.54) | KDR | |
| SCHEMBL5067404 | 0.81 | CSF1R (0.41) | CSF1RPDGFRBPDGFRAFLT3MET | |
| SCHEMBL3660380 | 0.81 | KDR (0.48) | CSF1RPDGFRBPDGFRAFLT3MET | |
| SCHEMBL5060896 | 0.81 | CSF1R (0.42) | CSF1RPDGFRBPDGFRAFLT3MET | |
| SCHEMBL5067470 | 0.80 | KDR (0.44) | CSF1RPDGFRBPDGFRAFLT3MET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2146718-A1 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFERATIVE DISEASES AND OTHER PROLIFERATIVE DISEASES | Deciphera Pharmaceuticals, LLC. (US) | 2010-01-27 | — | — | EP | disclosed |
| WO-2008131253-A1 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFERATIVE DISEASES AND OTHER PROLIFERATIVE DISEASES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2008-10-30 | — | — | WO | disclosed |
| US-20080269254-A1 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFIC DISEASES AND OTHER PROLIFERATIVE DISEASES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269254-A1 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFIC DISEASES AND OTHER PROLIFERATIVE DISEASES | KIT, BRAF, RET | CSF1R 170/4885PDGFRB 178/4885PDGFRA 139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.